Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
122 hedge funds and large institutions have $1.2B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 19 reducing their positions, and 10 closing their positions.
370% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 10
158% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 19
130% more capital invested
Capital invested by funds: $522M → $1.2B (+$680M)
44% more funds holding
Funds holding: 85 → 122 (+37)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
39% less call options, than puts
Call options by funds: $5.44M | Put options by funds: $8.87M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$75.7M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$39M |
| 3 |
Millennium Management
New York
|
+$36.5M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$36M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$34.3M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
-$30.5M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$11.6M |
| 4 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$11.1M |
| 5 |
EP
Eversept Partners
New York
|
-$8.38M |
DCPH Hedge Fund Activity: Q3 2019 in Review
122 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2019, worth a combined $1.2B — up 130% from $522M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new DCPH positions and 10 closed out — a net gain of 37 holders — while 49 added to existing stakes and 19 trimmed.
The largest buyer was Redmile Group, adding an estimated $75.7M. The largest seller was OrbiMed, cutting an estimated $34.3M.
- 122 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2019, up from 85 in Q2 2019.
- Funds reported $1.2B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2019, up 130% quarter-over-quarter.
- 47 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 10 closed out, a net change of +37 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was Redmile Group, an estimated $75.7M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was OrbiMed, an estimated $34.3M sold.
Based on aggregated 13F filings for Q3 2019.